Amicus Therapeutics Inc.’s plan to spin off its gene therapy work by way of the combination with blank check firm Arya Sciences Acquisition Corp. IV “allows us to be laser-focused on maximizing the opportunity for Galafold [migalastat]” while setting up launch preparations for AT-GAA, said Bradley Campbell, chief operating officer.